Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion

Summary

• Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%.
• Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025.
• Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.
• The global Sezary Syndrome market is expected to reach $2.34 billion by 2037.
• Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

quantic69/iStock via Getty Images

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.